4-1BB/4-1BBL Signaling Pathway

Figure 1. 4-1BB/4-1BBL signaling pathway


TCR ligation of T cells transiently induces expression of 4-1BB (also known as CD137 or TNFRSF9, encoded by TNFRSF9), a fellow of the TNF receptor superfamily. 4-1BB was originally identified in mice by a modified differential screening procedure. The human homologue of 4-1BB (CD137) was cloned from activated human T-cell leukemia virus type 1-transformed human T-lymphocytes library. Human 4-1BB resides on chromosome 1p3613, in a cluster of related genes including TNFR2, CD30, OX40 and TAMP/Apo3, which have been shown to be mutated in several malignancies. From previous studies, we can know that the human 4-1BB contains 255 a.a. with two potential N-linked glycosylation sites. Hydrophobicity analysis predicted that 4-1BB has a putative signal peptide, an extracellular domain, a transmembrane region and a short intracellular domain. The molecular weight of the protein was calculated to be 27 kDa and was shown to be 60% identical to murine 4-1BB. In the cytoplasmic domain, five regions of a.a. sequences were conserved between mice and human, indicating that these residues might be important for 4-1BB function.

The ligand of 4-1BB was first confirmed in the EL4 cell line through its binding with a fusion 4-1BB/Fc protein. The 4-1BBL gene was then cloned through the screening of an EC1 cDNA expression library. Human 4-1BBL was first isolated in 1994 by Alderson and his colleagues. They used a fusion protein consisting of the extracellular portion of human 4-1BB coupled to the Fc region of human immunoglobulin (Ig) G1 to identify and clone the gene for human 4-1BBL from an activated CD4+ T-cell clone using a direct expression cloning strategy. Sequence analysis showed that human 4-1BBL consisted of 254 a.a. and shared a 36% identity with murine 4-1BBL. Fluorescence in situ hybridization analyses or FISH analysis showed that the human 4-1BBL gene mapped to chromosome 19 in the region 19p13.3. Hydrophobicity analysis predicted that human 4-1BBL has a signal hydrophobic domain, while the absence of a signal sequence suggested that 4-1BBL was a type II membrane glycoprotein with a single predicted transmembrane segment.

The function of pathway

4-1BB is a co-stimulatory molecule with roles in expansion, acquisition of effector function, survival, and development of T cell memory. In addition to being expressed on activated T cells, 4-1BB is also expressed on several cell types in the hematopoietic lineage, as well as endothelial and epithelial cells. 4-1BBL (TNFSF9), the primary ligand of 4-1BB, is expressed predominantly on professional APC populations, B cells, macrophages and other cell types and binds with 4-1BB to induce signaling through TRAF1 and TRAF2 to activate the NF-κB, AKT, p38 MAPK, and ERK pathways. These signaling pathways induce the expression of survival genes encoding survivin, Bcl-2, Bcl-XL, and Bfl-1 and decrease the expression of pro-apoptotic Bim. Therefore, 4-1BB/4-1BBL signaling pathway can promote different type cells to live. Interestingly, the phenotype in response to virus challenge differs between 4-1BB and its ligand. For example, 4-1BBL-deficient mice show reduced accumulation of memory CD8+ T cells, whereas 4-1BB deficient mice have decreased memory but enhanced accumulation of acute CD8+ T cells. This type of result implicates bidirectional signaling or a distinct receptor signaling mechanism. Other models of infectious disease have shown that the effect of 4-1BB blockade depends upon the context and disease features. For instance, infections that are quickly cleared or produce minimal inflammation are often unaffected by 4-1BB deficiency, whereas chronic or highly inflammatory disease requires 4-1BB for memory development and/or viral clearance.

Clinical significance

4-1BB has also been involved in autoimmune disorders and graft versus host disease (GVHD). Studies in multiple models of inflammatory and autoimmune disease have all demonstrated a reduced disease severity following therapy that targets the 4-1BB-4-1BBL signaling interaction. Antibody blockade or genetic knockout of 4-1BB has improved disease pathology and decreased production of cytokines by CD4+ T cells. Clinical studies have demonstrated an increase in serum levels of soluble 4-1BB in patients with multiple sclerosis and rheumatoid arthritis, suggesting that 4-1BB might be a useful biomarker for disease severity, as well as a target for clinical trial. Interestingly, stimulation of 4-1BB signaling with an agonist monoclonal antibody (mAb) also ameliorates allograft response and autoimmune disorders in preclinical models. Agonist 4-1BB antibodies appear to work both by inducing apoptosis of over-stimulated, pathogenic CD8+ T cells and by expanding indoleamine 2,3-dioxygenase-expressing DCs that induce differentiation of suppressive Treg cell populations. Paradoxically, stimulation of 4-1BB with agonist antibodies also inhibits inflammation in many murine models of autoimmunity, which may be due to augmenting regulatory CD8 T cell activity and/or driving death of pathogenic CD4 T cells. These results indicate that the context of 4-1BB blockade or stimulation will be essential for identifying the best therapeutic approach for each disorder. 4-1BB may also control sepsis and biliary cirrhosis. 4-1BB-deficient mice exhibit lower mortality in a model of sepsis driven by cecal ligation and puncture, and similar results are produced by blocking 4-1BBL in wild-type mice. In patients with primary biliary cirrhosis, there is additionally a positive correlation between expression of soluble and membrane 4-1BBL and mRNA for 4-1BBL, with serum levels of disease markers such as bilirubin, γ-glutamyltransferase, and interleukin (IL) -18.

Besides, stimulating 4-1BB has also been an attractive candidate for application to cancer immunotherapy, particularly because 4-1BB agonists can enhance the rescue of T cells tolerized by chronic antigen exposure and reduce the burden of established tumors in preclinical models. Recent studies in murine models have suggested that using a lower dose of agonist anti-4-1BB mAb in combination with another immune modulator, such as anti-PD-1 or anti-CTLA-4 mAb, might be active against tumors without inducing toxicity. The signaling domain of 4-1BB is also a common component of the chimeric antigen receptor (CAR) construct for T cell immunotherapy in clinical trials and development. This approach uses genetic engineering to introduce a tumor-specific antibody fragment linked to intracellular TCR CD3ζand 4-1BB signaling domains to activate cytotoxic activity of CD8+ T cells after antibody-antigen recognition. Use of the 4-1BB signaling domain leads to prolonged survival of CAR T cells in vitro and the development of a central-memory phenotype associated with increased oxidative metabolism. Importantly, incorporation of 41BB in the CAR construct avoids the toxic effects associated with agonist mAb therapy.


  1. Michael C., et al. TNF superfamily in inflammatory disease: translating basic insights. Trends in Immunology, 2012, 33: 144-152.
  2. Lindsay K., et al. The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses. Immunity Review, 2016, 44: 1005-1019.
  3. Leukaemia S. L., et al. Role of 4-1BB:4-1BB ligand in cancer immunotherapy. Cancer Gene Therapy, 2004, 11: 215–226.
  4. Dass S. V., Byoung S. K. 4-1BB signaling beyond T cells. Cellular & Molecular Immunology, 2011, 8: 281–284.
  5. Seong-A J., et al. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunology and Cell Biology, 2005, 83: 344–351.

Return to Resources

Inquiry Basket